1. Home
  2. IMNM vs ALRM Comparison

IMNM vs ALRM Comparison

Compare IMNM & ALRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$23.85

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo Alarm.com Holdings Inc.

ALRM

Alarm.com Holdings Inc.

N/A

Current Price

$55.43

Market Cap

2.8B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
IMNM
ALRM
Founded
2006
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.8B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
IMNM
ALRM
Price
$23.85
$55.43
Analyst Decision
Strong Buy
Hold
Analyst Count
10
3
Target Price
$32.80
$56.67
AVG Volume (30 Days)
884.8K
318.8K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
7.42
EPS
N/A
0.95
Revenue
$6,941,000.00
$1,011,187,000.00
Revenue This Year
N/A
$7.00
Revenue Next Year
$1,127.34
$4.53
P/E Ratio
N/A
$58.17
Revenue Growth
N/A
7.59
52 Week Low
$8.93
$41.49
52 Week High
$30.06
$58.15

Technical Indicators

Market Signals
Indicator
IMNM
ALRM
Relative Strength Index (RSI) 35.85 47.22
Support Level $23.67 $54.07
Resistance Level $25.07 $58.03
Average True Range (ATR) 1.00 1.28
MACD -0.59 -0.36
Stochastic Oscillator 6.86 27.20

Price Performance

Historical Comparison
IMNM
ALRM

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About ALRM Alarm.com Holdings Inc.

Alarm.com Holdings Inc has a cloud-based platform that offers an expansive suite of IoT solutions addressing world-wide opportunities in the residential, multi-family, small business and enterprise commercial markets. It has two reportable segments: Alarm.com & Other. The Alarm.com segment represents the cloud-based Software platforms for intelligently connected property & related solutions. The other segment is focused on researching, developing & offering residential & commercial automation solutions & energy management products & services in adjacent markets. The majority of revenue is from the Alarm.com segment. The platform allows home & business owners to secure their properties and automate & control an array of connected device.

Share on Social Networks: